Moderna’s influenza vaccine superior to licensed shot in study
Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study.
Shares of the company were up 5.4% in premarket trading following the results.
The vaccine, mRNA-1010, was 26.6% more effective than GSK’s approved shot in the overall study population, which included 40,805 adults aged 50 years and older, Moderna said.
The company said its mRNA-based shot has the potential advantage to more precisely match circulating strains and support rapid response in a future influenza pandemic.
The biotech is also working flu and COVID combination vaccine candidate, but had withdrawn its application seeking approval for it in May to wait for efficacy data from the flu shot trial.
Moderna said it plans to engage with regulators on filing submissions for the flu vaccine candidate.
